Efficacy and safety profile of combining programmed cell death‐1 (PD‐1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non‐small cell lung cancer (NSCLC)

BACKGROUND: Previous studies have demonstrated that PD‐1 inhibitors are effective in the treatment of advanced or metastatic non‐small cell lung cancer (NSCLC). However, whether the combination of PD‐1 inhibitors and antiangiogenic agents benefit advanced NSCLC patients as subsequent therapy remains...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Ziyi, Li, Teng, Hu, Xingsheng, Hao, Xuezhi, Xing, Puyuan, Li, Junling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410518/
https://www.ncbi.nlm.nih.gov/pubmed/34268872
http://dx.doi.org/10.1111/1759-7714.14078

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410518/
https://www.ncbi.nlm.nih.gov/pubmed/34268872
http://dx.doi.org/10.1111/1759-7714.14078

Ejemplares similares